Lexicon Pharmaceuticals, Inc. Share Price & Technical Analysis
LXRX · $2.16 (-3.14%)
Healthcare / Biotechnology
$2.16
-3.14%
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
38% return in May, 10% avg return in past 3 year May month.
88% return in 2026, 46% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 36% | 14% | 0% | 38% | – | – | – | – | – | – | – | 88% |
| 25 | 14% | -12% | 25% | 40% | -14% | 50% | 22% | 0% | 27% | 0% | 0% | -21% | 131% |
| 24 | 27% | 25% | 0% | -40% | 6% | 0% | 29% | -23% | -6% | 25% | -33% | -12% | -2% |
| 23 | 16% | 0% | 4% | 0% | 38% | -15% | -13% | -15% | -35% | 9% | -15% | 36% | 10% |
| 22 | -18% | -34% | 0% | -14% | 0% | 6% | 26% | 17% | -14% | -8% | -5% | -14% | -59% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.06B
P/E ratio
—
52W high
$2.53
52W low
$0.62
Volume
16,25,337
Beta
0.97
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Lexicon Pharmaceuticals, Inc. share price today?
- Lexicon Pharmaceuticals, Inc. (LXRX) last traded around $2.16 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LXRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LXRX. Download the app for real-time alerts.
- How can I analyze Lexicon Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.